Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Japan Biosimilar Association Says “Authorized Biosimilars” Could Mar Industry Development
The Japan Biosimilar Association issued a statement on May 16, alarming that “authorized biosimilars (AB)” could threaten the healthy development of the biosimilar industry in Japan - a de-facto caution against moves by companies like Kyowa Hakko Kirin, which recently…
To read the full story
Related Article
- MHLW Official Expounds on “Authorized Biosimilar” Pricing, 50% Generic Rule Applies for “Biosame” Products
July 11, 2018
- MHLW Study Group to Issue Report Calling for Guidelines to Promote Efficient Development of Biosimilars
May 18, 2017
- Chugai to Mull Authorized Biosimilars for 3 Key Cancer Meds on “Case-by-Case Basis”
February 2, 2017
- Kyowa Kirin Sets Up New Firm for Nesp Authorized Biosimilar
February 1, 2017
ORGANIZATION
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- JPMA Mulls Proposal to Standardize PMDA Review Reports
April 27, 2026
- JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
April 24, 2026
- APAC Disbands Drug Discovery WG as Asia Capabilities Rise
April 23, 2026
- Flight Cuts, Fuel Costs Tied to Iran Crisis Threaten API Imports: Trader
April 23, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…